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Laura Biederman, MD and Amity Roberts, Ph.D., D(ADMM) 
Department of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College at Thomas 
Jefferson University, Philadelphia, PA 19107 
Introduction 
    HIV-1 genotype (GHIV), HIV-1 Integrase (HIV1I) and HIV-1 Trophile (HIV1T) assays 
are sendout tests that incur a significant financial burden on the laboratory when 
ordered on inpatients who do not receive follow-up clinic visits.  For these assays to 
be utilized in guiding antiretroviral therapy, the patient must receive follow-up.  It 
will reduce the sendout budget by restricting these tests to the outpatient clinic 
setting. 
Methods 
    The number of GHIV, HIV1I and HIV1T tests ordered between 1/5/13 and 
1/5/14 were collect.  These data were then analyzed based on test, ordering 
provider specialty and post-inpatient follow-up.  The data was organized into 
test type and further categorized by order setting (inpatient vs outpatient), and 
ordering clinician specialty.  Clinical follow up was then analyzed for each of the 
categories.   
Results 
GHIV:  There were 68 patients for which GHIV was ordered, 32% (n =23) of 
whom did not have follow-up.  The specialty who had the largest percentage of 
un-followed up tests was Hospital Medicine with 63% of their ordered tests not 
having follow up (n=12).  Of the 68 GHIV ordered,  46% were ordered in the 
inpatient setting with 60% of those orders not receiving follow-up and 
represent a total cost of $6,300 for the institution. 
HIV1I:  A total of 7 HIV1I tests were ordered during the time period examined.  
Of these 7 tests, only one was ordered as an inpatient.  This one test was not 
appropriately followed up on and represented a net cost to the hospital of $725.  
Interestingly, this test had an overall follow up rate of 71% (n=5). 
HIV1T:  Of the 6 HIV1T tests ordered, only one of the tests was ordered 
inpatient, and all of the patients who had this test done received appropriate 
follow up.    The one HIV1T assay  ordered inpatient  represented a cost of 
$3,055.   
The total amount of money lost due to lack of clinic follow-up was $10,550 for 
the laboratory.   
 
Conclusion 
   HIV genotyping represents a significant cost for the hospital, that is wasted if 
there is no follow up.   Especially when ordered in the inpatient setting, the lack 
of follow up confers a significant cost to the institution.  The total amount spent 
by the laboratory on genotyping assays which did not have follow-up during 12 
months (inpatient and outpatient) was $10,550.  If testing were to be restricted 
to the outpatient clinic setting there would be a savings of $15,330 annually.   
Based on this data, ordering of these tests should be at least restricted in the 
inpatient setting to those patients who are being followed by infectious disease 
in order to mitigate inappropriate ordering. 
GHIV Follow Up 
Fig 1: GHIV orders divided into patients who did receive follow up and those who 
did not receive follow up by ordering location (inpatient vs outpatient). 





Infectious Disease 23 85% 4 15% 27 
Emergency Medicine 3 50% 3 50% 6 
Family Medicine 6 75% 2 25% 8 
Medicine 7 37% 12 63% 19 
Other 6 75% 2 25% 8 
GHIV Follow Up by Ordering Specialty 
HIV1I Follow Up 
HIV1I Follow Up by Ordering Specialty 
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Table 1: GHIV orders by ordering specialty and follow up 
utilization. 
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Fig 2: HIV1I orders divided into patients who did receive follow up and those who 
did not receive follow up by ordering location (inpatient vs outpatient). 
Cost of HIV Genotyping Ordered on Inpatients 
Fig 3: Total cost of HIV genotyping ordered inpatient divided by follow up. 
$8,305 
$7,025 
Table 3: Total cost of HIV genotyping (GHIV and HIV1I)  
lost to follow up by test type and ordering location 
(inpatient vs outpatient). 
Cost of HIV Genotyping Without Follow Up 
Inpatient Outpatient Total 
GHIV $7,350  $1,750  $9,100  
HIV1I $725  $725  $1,450  
Total $8,075  $2,475  $10,550  
